health

BD - dedicated to improving people’s health

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents.

The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases.

Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

BD has a history of innovation in the medical devices and technology area. In 1924, BD manufactured its first syringe made specifically for insulin injection. In 1947, BD introduced the Vacutainer system, improving the quality of blood samples by evacuating specimens directly into tubes.

In 1950, the first sterile disposable blood collection set was developed and sold to the American Red Cross. In 1952, BD provided sterilisation expertise to NASA for the first Viking mission to Mars and 1973, BD - with Stanford University - manufactured its first FACS instrument, pioneering the company’s involvement in cytology.

In Sri Lanka BD has been a regular supplier to SPC since 2004, for a range of products including disposable syringes and spinal anaesthesia needles. BD has been the recipient of the “merit award - best supplier surgical category”, for the last three years in a row.

BD is known worldwide for the extensive training, education and value added services to its customers. To provide the same to Sri Lankan customers and to increase it presence in the growing private market, BD has now positioned a senior manager here in Colombo itself.

Baur and Co. are the local agents for BD, and encouraged by the support from BD. This will enable the company to better support their existing and prospective customers through various initiatives like training on clinical applications of flowcytometry eg. Leukemia and Lymphoma, best-in-class programmes on injection and infusion safety, blood collection and infections disease diagnosis.